Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune...

Full description

Bibliographic Details
Main Authors: Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng
Format: Article
Language:English
Published: Taylor & Francis Group 2024-01-01
Series:Mycology
Subjects:
Candidiasis
secukinumab
ixekizumab
brodalumab
bimekizumab
IL-17 inhibitors
Online Access:https://www.tandfonline.com/doi/10.1080/21501203.2023.2265664

Similar Items

Similar Items